Ipilimumab/nivolumab/pembrolizumabInterstitial pneumonitis, hepatitis and colitis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1712卷 / 1期

关键词：

D O I：

10.1007/s40278-018-49603-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：314 / 314

相关论文

共 50 条

[1] Ipilimumab/nivolumab/pembrolizumabInterstitial nephritis: case report
Reactions Weekly, 2019, 1763 (1) : 204 - 204
[2] Ipilimumab/nivolumab/pembrolizumabAcute hepatitis and immune-related colitis: case report
Reactions Weekly, 2019, 1742 (1) : 134 - 134
[3] PembrolizumabInterstitial bilateral pneumonitis: case report
Reactions Weekly, 2021, 1846 (1) : 257 - 257
[4] Ipilimumab/nivolumabMicroscopic colitis, thyroiditis and pneumonitis: case report
Reactions Weekly, 2020, 1808 (1) : 159 - 159
[5] Ipilimumab/pembrolizumabInterstitial granulomatous dermatitis: case report
Reactions Weekly, 2018, 1726 (1) : 219 - 219
[6] Ipilimumab/nivolumab/prednisolonePemphigus vulgaris, pneumonitis and lack of efficacy: case report
Reactions Weekly, 2023, 1978 (1) : 214 - 214
[7] Ipilimumab/nivolumabDermatitis, colitis and hepatitis: case report
Reactions Weekly, 2021, 1838 (1) : 288 - 288
[8] Ipilimumab/nivolumab/pembrolizumabAcute hepatitis, colitis and diverticulitis: 4 case reports
Reactions Weekly, 2018, 1725 (1) : 185 - 185
[9] Ipilimumab/nivolumab/pembrolizumabImmune-related colitis, pneumonitis and thyroiditis: 3 case reports
Reactions Weekly, 2023, 1948 (1) : 246 - 246
[10] Ipilimumab/nivolumab/pembrolizumabLack of efficacy, hepatitis and hepatitis relapse: case report
Reactions Weekly, 2023, 1975 (1) : 200 - 200

← 1 2 3 4 5 →